Abstract
Get full access to this article
View all access options for this article.
References
1.
Keam
SJ
. Tapinarof Cream 1%: First Approval . Drugs . 2022 ; 82 (11 ):1221 –1228 ; doi: 10.1007/s40265-022-01748-6. Erratum in: Drugs. 2022 Aug 17; Erratum in: Drugs. 2022 Sep;82(13):1433.
2.
Tolaymat
L
,
Hall
MR
Perioral dermatitis . In: StatPearls [Internet] . Treasure Island, FL : StatPearls Publishing ; 2023 .
3.
Silverberg
JI
,
Eichenfield
LF
,
Hebert
AA
et al. Tapinarof cream 1% once daily: Significant efficacy in the treatment of atopic dermatitis in two pivotal phase 3 trials in adults and children down to 2 years of age . Br J Dermatol . 190 (Supplement_2 ):ii17 –ii18 ; doi: 10.1093/bjd/ljad498.021
4.
Eyerich
K
,
Eyerich
S
Immune response patterns in non-communicable inflammatory skin diseases . J Eur Acad Dermatol Venereol . 2018 ; 32 (5 ):692 –703 ; doi: 10.1111/jdv.14673
5.
Balić
A
,
Vlašić
D
,
Mokos
M
et al. The role of the skin barrier in periorificial dermatitis . Acta Dermatovenerol Croat . 2019 ; 27 (3 ):169 –179 .